Loxo Oncology at Lilly (LLY), and Foghorn Therapeutics Inc. (FHTX) have entered a strategic collaboration to create oncology medicines by applying Foghorn's Gene Traffic Control platform. Foghorn will receive upfront consideration of $300 million in cash for the collaboration agreement. Foghorn will also receive an equity investment by Lilly of $80 million in Foghorn common shares at a price of $20 per share.
The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program and an additional undisclosed oncology target. Foghorn is eligible to receive royalties on ex-U.S. sales starting in the low double-digit range and escalating into the twenties.
Also, the collaboration includes three additional discovery programs using Foghorn's Gene Traffic Control platform. Foghorn may receive up to a total of $1.3 billion in potential development and commercialization milestones.
Lilly noted that there will be no change to the company's 2021 non-GAAP earnings per share guidance as a result of the deal.
Foghorn Therapeutics is developing multiple product candidates in oncology with two currently being investigated in clinical studies.
Shares of Foghorn Therapeutics were up 33% in pre-market trade on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.